Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk ® Hereditary Cancer Test with RiskScore ® study has been named in the ...

- The evidence suggests that cognitive assessment tools that are completed by people themselves could be used in the detection and diagnosis of dementia. - There is not enough evidence to recommend ...

Agreement Reached on Primary Endpoint and Phase 3 Trial Design. Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering. FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE ...

Extension and the Nevada Association of Counties complete assessment that highlights the lack of public health infrastructure ...

Hyderabad: A five-day intensive course on pre-clinical toxicology and risk assessment was recently held at the University of ...

Devices that are approved through a process that does not require any clinical evidence for FDA authorization should not ...